Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

Style Box ETF report for USMV

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note

Eli Lilly (LLY) reachead $608.31 at the closing of the latest trading day, reflecting a -1.35% change compared to its last close.

Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain

Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.

Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals

Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates

Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.

The Zacks Analyst Blog Highlights Meta Platforms, Eli Lilly, Caterpillar, Citigroup and Micron Technology

Meta Platforms, Eli Lilly, Caterpillar, Citigroup and Micron Technology are part of the Zacks top Analyst Blog.

Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study

Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.

Sheraz Mian headshot

Top Research Reports for Meta Platforms, Eli Lilly & Caterpillar

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY) and Caterpillar Inc. (CAT).

Lilly (LLY) Moves 4.5% Higher: Will This Strength Last?

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts

A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.

The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer

Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates

Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why

Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.

Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

Eli Lilly (LLY) concluded the recent trading session at $531.46, signifying a +1.19% move from its prior day's close.

ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data

Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.

Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio

Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.

ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day

ACM Research and Advance Auto Parts have been highlighted as Zacks Bull and Bear of the Day.

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.